{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:28:32Z","timestamp":1795188512228,"version":"4.10.3"},"reference-count":69,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec id=\"ab-eoi250039-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Semaglutide is a widely used treatment for diabetes and obesity, offering considerable cardiovascular benefit. However, its association with ocular adverse events remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250039-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the incidence of eye disorders, diabetic retinopathy, and nonarteritic anterior ischemic optic neuropathy (NAION) in adults treated with semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250039-6\">\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A comprehensive electronic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted on April 10, 2025, without date restrictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250039-7\">\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Investigators independently screened records to identify randomized clinical trials comparing semaglutide with either an active comparator or placebo in adults, assessing ocular adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250039-8\">\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>Descriptive synthesis of the included studies was performed. The random-effects model using the inverse variance method was used to summarize the odds ratio (OR) for eye disorders and diabetic retinopathy. Peto OR with a fixed-effects model was applied for NAION. Risk of bias was assessed with the RoB 2.0 tool and quality of evidence with GRADE. Trial sequential analysis (TSA) was performed to determine whether the available data were sufficient for definitive conclusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250039-9\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes included the number of patients experiencing an ocular adverse event, diabetic retinopathy, or NAION. Subgroup analyses were conducted based on follow-up duration, comparator type, and primary baseline condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250039-10\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 78 trials with 73\u202f640 participants were included. Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17). Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02). Overall risk of bias was low. TSA provided evidence that the sample size was sufficient to avoid missing alternative results for diabetic retinopathy but not for NAION.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250039-11\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>These findings suggest that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. Despite the fact that an association between semaglutide treatment and NAION was found, current evidence remains insufficient to establish definitive conclusions regarding its association with NAION. Further studies with larger sample sizes and adequate evaluation of NAION are warranted to clarify this potential risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.2489","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:31:07Z","timestamp":1755185467000},"page":"759","source":"Crossref","is-referenced-by-count":49,"title":["Ocular Adverse Events With Semaglutide"],"prefix":"10.1001","volume":"143","author":[{"given":"Gabriella R.","family":"Natividade","sequence":"first","affiliation":[{"name":"Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Post-graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Division of Endocrinology and Metabolism, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo F.","family":"Spiazzi","sequence":"additional","affiliation":[{"name":"Post-graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus W.","family":"Baumgarten","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bassotto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afonso A.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna L.","family":"Fraga","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno G.","family":"Scalco","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Mattes","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lavinsky","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Post-graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Division of Ophthalmology, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline K.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Mount Sinai hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gerchman","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Post-graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil"},{"name":"Division of Endocrinology and Metabolism, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"eoi250039r1","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"eoi250039r2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"eoi250039r3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide.","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi250039r4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"eoi250039r5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/vision7040072","article-title":"Non-arteritic anterior ischemic optic neuropathy (na-aion): a comprehensive overview.","volume":"7","author":"Salvetat","year":"2023","journal-title":"Vision"},{"issue":"12","key":"eoi250039r6","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.ophtha.2016.08.017","article-title":"Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy.","volume":"123","author":"Cestari","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi250039r7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.ophtha.2011.01.054","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients.","volume":"118","author":"Lee","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi250039r8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00041327-199403000-00011","article-title":"Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. population-based study in the state of Missouri and Los Angeles County, California.","volume":"14","author":"Johnson","year":"1994","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"eoi250039r9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy.","volume":"123","author":"Hattenhauer","year":"1997","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"eoi250039r10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/bjophthalmol-2017-311140","article-title":"Prevalence and incidence of non-arteritic anterior ischaemic optic neuropathy in South Korea: a nationwide population-based study.","volume":"102","author":"Lee","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"eoi250039r11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study.","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi250039r12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"issue":"5","key":"eoi250039r13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"eoi250039r14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/dc15-0165","article-title":"A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes.","volume":"39","author":"Nauck","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"eoi250039r15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"eoi250039r16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"eoi250039r17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial.","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"eoi250039r18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial.","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"eoi250039r19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"eoi250039r20","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial.","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"eoi250039r21","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"eoi250039r22","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.2337\/dc17-2381","article-title":"A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin.","volume":"41","author":"Lingvay","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"eoi250039r23","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s13300-018-0442-0","article-title":"No QTc prolongation with semaglutide: a thorough QT study in healthy subjects.","volume":"9","author":"Demmel","year":"2018","journal-title":"Diabetes Ther"},{"issue":"2","key":"eoi250039r24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"eoi250039r25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial.","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"eoi250039r26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"eoi250039r27","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes.","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"10192","key":"eoi250039r28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"eoi250039r29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"eoi250039r30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"eoi250039r31","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial.","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"eoi250039r32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"eoi250039r33","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"eoi250039r34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"5","key":"eoi250039r35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial.","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"eoi250039r36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"eoi250039r37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001649","article-title":"Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.","volume":"8","author":"Buse","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"eoi250039r38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"eoi250039r39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial.","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"10278","key":"eoi250039r40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"eoi250039r41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"eoi250039r42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"eoi250039r43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial.","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"eoi250039r44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"eoi250039r45","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial.","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"eoi250039r46","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"eoi250039r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108472","article-title":"Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: a prespecified secondary analysis of a randomised clinical trial.","volume":"37","author":"Gullaksen","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"3","key":"eoi250039r48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-003206","article-title":"Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous semaglutide randomized pragmatic (SEPRA) trial.","volume":"11","author":"Buse","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"eoi250039r49","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"eoi250039r50","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdi.14000","article-title":"Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: a randomized controlled trial.","volume":"14","author":"Iijima","year":"2023","journal-title":"J Diabetes Investig"},{"issue":"10403","key":"eoi250039r51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"eoi250039r52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s42255-023-00943-3","article-title":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.","volume":"6","author":"Dwibedi","year":"2024","journal-title":"Nat Metab"},{"issue":"3","key":"eoi250039r53","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"eoi250039r54","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes.","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"eoi250039r55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"eoi250039r56","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.","volume":"106","author":"Selvarajah","year":"2024","journal-title":"Kidney Int"},{"issue":"9","key":"eoi250039r57","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s00125-024-06133-4","article-title":"Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, phase IIIa, randomised trial.","volume":"67","author":"Ji","year":"2024","journal-title":"Diabetologia"},{"issue":"9","key":"eoi250039r58","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","article-title":"Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, phase IIIa, randomised trial.","volume":"67","author":"Wang","year":"2024","journal-title":"Diabetologia"},{"issue":"9","key":"eoi250039r59","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10489","key":"eoi250039r60","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"issue":"20","key":"eoi250039r61","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes.","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"9131","key":"eoi250039r62","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"eoi250039r63","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC.","volume":"64","author":"Lachin","year":"2015","journal-title":"Diabetes"},{"issue":"1","key":"eoi250039r64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes.","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metab"},{"issue":"1","key":"eoi250039r65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40261-021-01110-w","article-title":"Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.","volume":"42","author":"Wang","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"3","key":"eoi250039r66","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy.","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"9","key":"eoi250039r67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076653","article-title":"The association between diabetes mellitus and nonarteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis.","volume":"8","author":"Chen","year":"2013","journal-title":"PloS One"},{"issue":"5","key":"eoi250039r68","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00417-021-05522-4","article-title":"Cardiometabolic factors and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis.","volume":"260","author":"Chatziralli","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"eoi250039r69","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.18240\/ijo.2021.07.12","article-title":"Atherogenic indices in non-arteritic ischemic optic neuropathy.","volume":"14","author":"Ko\u00e7ak","year":"2021","journal-title":"Int J Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2837461\/jamaophthalmology_natividade_2025_oi_250039_1758049770.92594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:18:58Z","timestamp":1758208738000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2837461"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.2489","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}